San Antonio, TX / San Francisco, CA – December 12, 2023 – A groundbreaking new study published today in the prestigious journal JAMA and presented at the San Antonio Breast Cancer Symposium is poised to fundamentally reshape the landscape of breast cancer screening. Challenging decades of conventional wisdom, the first phase of the WISDOM study suggests that a personalized approach, meticulously tailored to a woman’s individual risk profile, is not only more effective but also safer than the long-standing practice of routine annual mammograms for all.
This landmark research, coordinated by the University of California, San Francisco (UCSF), indicates a significant paradigm shift, moving away from a one-size-fits-all, age-based screening strategy towards a system built upon comprehensive risk evaluation. By matching screening frequency and modality to personal risk levels, researchers discovered a powerful new method to reduce the incidence of advanced cancer diagnoses while simultaneously ensuring individuals receive the precise level of screening they require. The findings illuminate a path toward more efficient allocation of healthcare resources and a more patient-centric approach to early detection and prevention.
Main Facts: A Paradigm Shift in Screening
The core message from the WISDOM study is unequivocal: the era of standardized, age-driven breast cancer screening is nearing its end. Instead, a future where screening protocols are dynamically adjusted based on a woman’s unique risk factors promises superior outcomes. This individualized strategy, meticulously validated through extensive research, not only maintains but potentially enhances the efficacy of early detection while mitigating the potential harms of over-screening.
Lead author Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center, emphasized the transformative potential of these findings. "These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," Dr. Esserman stated. "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies." Her assertion underscores the study’s ambition to instigate a systemic change that prioritizes precision medicine in breast cancer prevention.
The study’s primary objective was to directly compare the traditional annual mammography regimen with a novel, risk-based screening strategy. By analyzing a rich tapestry of data encompassing genetic information, lifestyle choices, comprehensive health history, and breast density, researchers were able to group participants into distinct risk categories, each warranting a different screening recommendation. This nuanced stratification allowed for a highly targeted approach, ensuring that women at higher risk received more intensive surveillance, while those at lower risk could potentially avoid unnecessary procedures and associated anxieties. Crucially, this personalized strategy demonstrated no increase in late-stage cancer diagnoses, affirming its safety and effectiveness.
Chronology: The Evolution of a Groundbreaking Study
The WISDOM study, an acronym for Women Informed to Screen Depending On Measures of Risk, represents a multi-year, ambitious undertaking designed to challenge and redefine breast cancer screening norms.
2016: The Genesis of WISDOM
The study officially launched in 2016, spearheaded by UCSF, with the ambitious goal of enrolling tens of thousands of women across the United States. Its initial phase sought to gather comprehensive data from a diverse cohort, setting the stage for a robust comparison between conventional and personalized screening methodologies. From its inception, WISDOM aimed to be a large-scale, pragmatic trial, reflecting real-world clinical scenarios and patient populations.
Phase One Data Collection and Analysis
The findings presented today are based on data collected from the first phase of the study, involving 46,000 women across various regions of the United States. These participants were enrolled with the express purpose of evaluating the safety and effectiveness of a risk-based screening approach. The study employed a randomized design, allowing for a direct comparison between women assigned to annual mammography and those assigned to a personalized screening schedule. An observational group was also included for women who chose their preferred screening strategy, providing valuable insights into patient acceptance.
December 12, 2023: Publication and Presentation
The culmination of this extensive research was the simultaneous publication of the findings in JAMA, one of the world’s most reputable medical journals, and a prominent presentation at the annual San Antonio Breast Cancer Symposium. This dual announcement amplified the study’s impact, immediately bringing its revolutionary findings to the attention of a global audience of clinicians, researchers, and policymakers. The timing underscores the urgency and significance of addressing long-standing questions about optimal breast cancer screening.
Ongoing Efforts: WISDOM 2.0 and Younger Participants
Since its launch, the WISDOM study has expanded its reach, enrolling more than 80,000 women to date. More recently, researchers have broadened the participant criteria to include women as young as 30. This expansion is a critical step in identifying individuals who may be at an increased risk of aggressive early-onset cancers due to inherited genetic variants, a demographic often overlooked by traditional age-based guidelines. The study is now progressing with WISDOM 2.0, an ongoing effort focused on refining risk assessment models even further, aiming to pinpoint women at higher risk for aggressive forms of the disease and provide them with exquisitely tailored long-term health strategies. This continuous evolution highlights the dynamic and forward-looking nature of the WISDOM initiative.
Supporting Data: Unpacking the Evidence for Personalized Screening
The compelling evidence supporting personalized breast cancer screening stems from the meticulous stratification of participants and the observed outcomes across different risk groups. The WISDOM study employed sophisticated, well-validated risk models to categorize women, moving beyond simple age to incorporate a holistic view of individual susceptibility.
The Limitations of Age-Alone Screening
For decades, breast cancer screening guidelines in the U.S. and many other countries have largely hinged on age, typically recommending regular mammograms starting at age 40 or 50. This approach, however, rests on the flawed assumption that most women face a similar baseline risk. As Dr. Esserman highlighted, research has long demonstrated that breast cancer risk is highly heterogeneous, influenced by a complex interplay of factors that age alone cannot capture. Relying solely on age can lead to over-screening for low-risk individuals, exposing them to unnecessary radiation, anxiety from false positives, and costly follow-up procedures. Conversely, it can result in under-screening for younger women or those with significant genetic predispositions, delaying the diagnosis of potentially aggressive cancers.
A Four-Tiered Risk-Based System
The WISDOM study’s innovation lies in its comprehensive risk assessment, which grouped participants into four distinct categories based on a deep analysis of age, genetic markers, lifestyle factors (such as diet and physical activity), personal health history, and breast density (a known independent risk factor).
-
Lowest Risk Group (26% of participants): For these women, representing a significant quarter of the cohort, the recommendation was to delay routine screening until age 50 or until an algorithmic assessment indicated their risk level had risen to that of a typical 50-year-old woman. This approach aims to reduce unnecessary exposure to radiation and the psychological burden of frequent screening for those with genuinely low risk.
-
Average Risk Group (62% of participants): The majority of participants fell into this category, for whom biennial (every two years) mammograms were advised. This frequency strikes a balance, providing effective surveillance without the intensity prescribed for higher-risk individuals.
-
Elevated Risk Group (8% of participants): Women in this group received a recommendation for annual mammograms, acknowledging their increased susceptibility and the need for more frequent monitoring to detect any changes early.
-
Highest Risk Group (2% of participants): This small but critical segment of the population was advised to undergo screening twice a year, alternating between mammography and MRI, irrespective of their age. This intensive surveillance reflects their significantly elevated risk, often due to strong genetic predispositions or a complex family history, where aggressive cancers can manifest at younger ages. MRI offers superior sensitivity for high-risk women, particularly those with dense breasts, complementing mammography.
Efficacy and Safety Metrics
A crucial finding from the study was that the personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses. This is a powerful validation, demonstrating that reducing screening frequency for lower-risk groups does not compromise early detection for the population as a whole. In fact, the individualized strategy was associated with a reduction in the likelihood of diagnosing more advanced cancers, suggesting that resources were effectively redirected to where they were most needed.
Patient Acceptance and Resource Allocation
Beyond clinical outcomes, the study also provided valuable insights into patient preferences. Among women who opted not to be randomized but joined an observational group, a striking 89% chose the risk-based screening strategy. This high rate of acceptance suggests a strong patient preference for a personalized approach, indicating that women are willing and eager to embrace screening protocols tailored to their individual circumstances.
Co-author Jeffrey A. Tice, MD, a UCSF professor of Medicine specializing in breast cancer risk assessment, underscored the efficiency gains. "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," Dr. Tice noted. This reallocation optimizes the use of healthcare resources, ensuring that more intensive and costly interventions are directed to those who stand to benefit most, while minimizing unnecessary procedures for others.
Personalized Prevention for Higher-Risk Women
The WISDOM study extended beyond just screening, offering customized prevention strategies for participants identified with elevated or highest risk. This included access to an online decision-making tool focused on breast health, direct consultation with a breast health specialist, and tailored recommendations. These recommendations encompassed crucial lifestyle modifications, such as improving diet and increasing physical activity, as well as discussions about the potential benefits of risk-reducing medications (e.g., selective estrogen receptor modulators like tamoxifen or raloxifene) for eligible individuals. This holistic approach integrates screening with proactive prevention, offering a comprehensive care pathway.
Official Responses: Voices for Change
The findings of the WISDOM study have elicited strong calls for reform from its lead researchers, signaling a consensus that current guidelines are outdated and inadequate for modern medical practice.
Dr. Laura J. Esserman, the driving force behind the study, articulated her vision for immediate and widespread change. "These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," she declared. Her emphasis on "transforming" and "altering" highlights the study’s ambition to not just refine but fundamentally redesign how screening is approached. Dr. Esserman’s perspective is rooted in the belief that an individualized assessment, which factors in genetic predispositions, biological markers, and lifestyle choices, is the only rational path forward for effective prevention strategies. Her leadership in this area, particularly at the UCSF Breast Care Center, positions her as a pivotal figure in advocating for these changes.
Dr. Jeffrey A. Tice, a co-author and expert in risk assessment tools, focused on the practical and systemic benefits. His statement, "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," speaks to the broader implications for healthcare systems. In an environment of finite resources, optimizing where and how screening dollars are spent can lead to better outcomes for a greater number of people. This isn’t just about individual patient care but about a more sustainable and equitable public health strategy.
Allison S. Fiscalini, MPH, director of the Athena Breast Health Network and the WISDOM study, highlighted one of the study’s most profound and potentially far-reaching contributions: its approach to genetic testing. "This is one of the first studies to offer genetic testing to all women, regardless of family history," Fiscalini noted. She emphasized the critical insight that "when used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." Her statement points to a future where genetic information is a routine component of health assessment, democratizing access to crucial risk insights that were previously limited by restrictive criteria.
Implications: Reshaping the Future of Breast Cancer Care
The WISDOM study’s findings carry profound implications across clinical practice, public health policy, and the broader understanding of breast cancer risk.
Transforming Clinical Guidelines:
The most immediate implication is the pressing need to revise existing clinical guidelines issued by bodies such as the American Cancer Society (ACS), the U.S. Preventive Services Task Force (USPSTF), and others. Current guidelines, largely age-based, will likely face intense scrutiny and pressure to incorporate comprehensive risk assessment. This transition will require significant effort in educating clinicians, developing standardized risk assessment tools that are easy to implement in routine practice, and ensuring equitable access to genetic testing and specialized counseling. The shift will not be instantaneous, but the compelling evidence from WISDOM provides a strong impetus for change.
Revolutionizing Genetic Testing:
One of the study’s most striking revelations was that 30% of women who tested positive for a genetic variant linked to higher breast cancer risk reported no family history of the disease. Under current clinical guidelines, many of these women would not typically qualify for genetic testing, leaving them unaware of their significantly elevated risk until potentially a late-stage diagnosis. This finding alone could lead to a massive expansion of genetic testing, moving it from a niche offering based on family history to a more universal screening component, especially for women as they approach screening age. Identifying these "hidden" high-risk individuals early opens doors for intensive surveillance and proactive prevention strategies, potentially saving countless lives.
Furthermore, the study’s evaluation of polygenic risk scores (PRS) marks a significant advancement. Beyond well-known pathogenic variants like BRCA1 and BRCA2, PRS combine the effects of numerous smaller DNA changes, offering a more nuanced and precise estimation of an individual’s lifetime breast cancer risk. This approach improved the precision of risk predictions and resulted in 12% to 14% of participants being reassigned to a different, more appropriate risk category. Integrating PRS into clinical practice could refine risk stratification even further, moving beyond Mendelian genetics to a more holistic genetic understanding.
Optimizing Resource Allocation and Reducing Harms:
The study’s emphasis on efficiency, as highlighted by Dr. Tice, has substantial implications for healthcare economics. By shifting resources from lower-risk women (who might be over-screened) to higher-risk women (who require more intensive surveillance), healthcare systems can achieve a better return on investment. This means fewer unnecessary mammograms, fewer false positives leading to biopsies and anxiety, and a more targeted application of advanced imaging techniques like MRI. This optimization not only improves patient experience but also frees up resources that can be directed towards other critical areas of care.
Empowering Patients and Enhancing Prevention:
The high acceptance rate of personalized screening among the observational group (89%) suggests that women are eager for more tailored information about their health. This approach empowers patients by providing them with a clearer understanding of their individual risk, enabling them to make more informed decisions about their screening and prevention strategies. The inclusion of personalized prevention guidance, covering lifestyle changes and risk-reducing medications, transforms screening from a passive detection process into an active engagement with long-term health and wellness.
Addressing Disparities and Promoting Equity:
By identifying high-risk individuals regardless of family history or other traditional criteria, personalized screening has the potential to address existing health disparities. Women from diverse backgrounds, who may not have comprehensive family health histories or access to specialist genetic counseling, could benefit immensely from universal risk assessment. However, careful implementation will be necessary to ensure that access to genetic testing, counseling, and advanced screening modalities is equitable across all socioeconomic and demographic groups.
The Future: WISDOM 2.0 and Beyond:
The ongoing WISDOM 2.0 study signifies the continuous evolution of this research. Its goal to further refine risk assessment, particularly in identifying women at higher likelihood of developing aggressive breast cancers, underscores the commitment to precision medicine. This next phase will likely explore advanced biomarkers, AI-driven risk prediction models, and integrate even more granular data to provide truly individualized, lifelong health strategies. The ultimate aim is not just to detect cancer earlier, but to prevent its most aggressive forms and ensure that every woman receives care perfectly attuned to her unique biological and lifestyle profile.
The WISDOM study represents a pivotal moment in the fight against breast cancer. By offering a meticulously validated, risk-based approach, it lays the groundwork for a future where screening is smarter, safer, more effective, and profoundly more personal. The coming years will undoubtedly see a concerted effort from the medical community to integrate these findings into standard practice, heralding a new era of breast cancer prevention and early detection.
Co-Authors: From UCSF, authors include Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD.
Other investigators are at UC Los Angeles; UC Irvine; UC San Diego; San Francisco VA Health Care System; Sanford Health in North Dakota; University of Chicago; Diagnostic Center of Miami; University of Alabama; Virginia Commonwealth University; Weill Cornell Medicine in New York; and the Karolinka Institutet in Stockholm.
Funding: Study support included the Patient Center Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation. Please see the paper for other funding sources.
Conflicts of Interest: Esserman is a medical advisory panel member for Blue Cross Blue Shield and has receive author fees from the UpToDate electronic medical information resource. Please see the paper for disclosures of other investigators.
About the Author
